Details

NameSymbolSector
MEDICAMEN BIOTECH LTD.MEDICAMEQPharmaceuticals
Open
282
High
287.8
Low
275
Close
285.75
Volume
60359
Exchange
nse
Time
08-Sep-2026

Outlook

Score:  

3

Rating:  

RISKY

Candlestick Pattern

Candle pattern of Medicamen Biotech is  
Short Body
Estimated Stoploss of Medicamen Biotech is ₹  
275
Medicamen Biotech has a  
Bullishℹ
 pattern. 
Formation of  
Short Body
 candle pattern indicates the trend direction of Medicamen Biotech is  
Unpredictableℹ
. 

Trend

Medicamen Biotech is in  
Sideways trendℹ
. 
Price of Medicamen Biotech is  
Upℹ
 by  

16.45

%. 
Target
Buy @ 

213.82

Sell @ 

276.42

Current @ 

285.75

Volume

The trades of Medicamen Biotech have been in  
Immenseℹ
 volume. 
The volume trades for Medicamen Biotech are  
Bullishℹ
 with  
Strong Buyersℹ
The trade volume of Medicamen Biotech is  

Up

 by  

61.37

% 

Valuation

The current market price of Medicamen Biotech is  
Overvaluedℹ

Financials

Balance
With total liablities and shareholder equity worth ₹ 297cr and total assets worth ₹ 297cr, the balance sheet of Medicamen Biotech is:  
Balancedℹ
. 
Cashflow
Medicamen Biotech has  
Badℹ
 cash flow because there is  

Shortage

 of  

₹ 11cr

. It is  
Downℹ
 by  

120

%. 

(*Mar 2025)

80% i.e. ₹ 8cr spent in operatingℹ
10% i.e. ₹ 1cr spent in investingℹ
10% i.e. ₹ 1cr spent in financingℹ
0% in otherℹ
Medicamen Biotech has  
Poorℹ
 cash flow because there is  

Shortage

 of  

₹ 5cr

. It is  
Downℹ
 by  

131.25

%. 

(*Mar 2024)

35.29% i.e. ₹ 6cr spent in operatingℹ
29.41% i.e. ₹ 5cr spent in investingℹ
35.29% i.e. ₹ 6cr earned in financingℹ
0% in otherℹ
Income
The income of Medicamen Biotech is  

₹ 47cr

 and  

Profit

 is :  

₹ 2cr

(*Sep 2025)

Medicamen Biotech Profit is up by:  

100

% and Income is Up by:  

9.3

% 

(*Sep 2025)

The income of Medicamen Biotech is  

₹ 43cr

 and  

Profit

 is :  

₹ 1cr

(*Jun 2025)

Medicamen Biotech Profit is up by:  

0

% and Income is Up by:  

26.47

% 

(*Jun 2025)

The income of Medicamen Biotech is  

₹ 34cr

 and  

Profit

 is :  

₹ 1cr

(*Mar 2025)

Medicamen Biotech Profit is down by:  

50

% and Income is Down by:  

24.44

% 

(*Mar 2025)

By using this site you agree to the use of cookies to deliver a better site experience.